RxDoctor Payments Data

Chlin Tennyson-Yemm

Psychiatric/Mental Health · Ringgold, GANPI 1629713375

Payments from drug & device makers

$661in general payments, 2019–2025

Across 13 payments — averaging $50.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$176
  • Corium, LLC$141
  • Otsuka America Pharmaceutical, Inc.$138
  • Teva Pharmaceuticals USA, Inc.$106
  • Acadia Pharmaceuticals Inc$34
  • Avanir Pharmaceuticals, Inc.$29
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$661100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$661 in reported general payments places this provider in the 60th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$115,398
Medicare patients
522
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate43$109,147
RexultiBrexpiprazole75$35,166
AustedoDeutetrabenazine16$23,684
Memantine Hcl513$14,183
Divalproex Sodium379$11,169
Quetiapine Fumarate422$4,655
Sertraline Hcl633$4,611
Mirtazapine389$4,222
NuedextaDextromethorphan Hbr/Quinidine11$4,045
Buspirone Hcl415$3,467
Trazodone Hcl592$3,457
Rivastigmine18$3,005
Duloxetine Hcl220$2,828
Desvenlafaxine Succinate ErDesvenlafaxine Succinate52$2,107
Olanzapine239$1,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$34$109,14743 claims
Otsuka America Pharmaceutical, Inc.Rexulti$138$35,16675 claims
Teva Pharmaceuticals USA, Inc.Austedo$106$23,68416 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29$4,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Ringgold

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →